TTRX TTRX Weighted Average Exercise Price of Outstanding Options

Weighted Average Exercise Price of Outstanding Options at other companies

PTH

Pelthos Therapeutics Inc.PTHS

$16.17-72.3%

Arcutis Biotherapeutics, Inc.ARQT

$12.39+42.7%

Tarsus Pharmaceuticals, Inc.TARS

$26.37+22.8%

Operating income-$1.2M-224%

Net income-$971.0K-196%

EPS (diluted)-$0.03-200%

Cash & equivalents$11.2M+613%

Total debt$6.0M—

Total equity$6.1M+647%

Total assets$18.6M—

Operating cash flow-$1.6M-448%

Market cap$217.45M-17.7%

Enterprise value$212.24M—

Return on equity-118.8%—

Debt / equity1×—

Current ratio2.2×—

Reported directly by TTRX in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice.

The official record: TTRX’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is TTRX's weighted average exercise price of outstanding options?: TTRX (TTRX) reported weighted average exercise price of outstanding options of 3.3 in Q1 2026.
What does weighted average exercise price of outstanding options mean?: This metric calculates the average price at which holders of outstanding stock options can purchase company shares. It provides context on the 'in-the-money' status of employee compensation packages. When compared to the current market price, it helps assess the alignment between employee incentives and shareholder value.